Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Lilly’s Omvoh shows strong one-year efficacy in pediatric ulcerative colitis, regulatory filing imminent.

What the company is saying

Eli Lilly and Company is highlighting positive one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients aged 6 to 17 with moderately to severely active ulcerative colitis. The company emphasizes that 81% of patients achieved clinical response at Week 12, and among these responders, 50% reached clinical remission at one year, which met the study’s primary endpoint. Secondary outcomes are detailed, including 71.2% symptomatic remission, 50% corticosteroid-free clinical remission without surgery, 73.1% clinical response, 53.8% endoscopic improvement, and 44.2% endoscopic remission at Week 52. Lilly frames Omvoh as the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC and plans to submit these data to global regulators for potential label expansion. The announcement features commentary from Mark Genovese, M.D., senior vice president of Lilly Immunology development, and Marla C. Dubinsky, M.D., a leading pediatric gastroenterologist, to reinforce the clinical and patient impact. The tone is confident, with a focus on unmet need and the potential for Omvoh to become the first-in-class therapy for this population.

What the data suggests

The SHINE-2 study enrolled 63 pediatric patients, with 54% having previously failed biologic therapy and half presenting with severe disease activity. At Week 12, 81% achieved clinical response to Omvoh induction. Among these responders (n=52), 50% achieved clinical remission at Week 52, the primary endpoint. Secondary endpoints at one year included 71.2% symptomatic remission, 50% corticosteroid-free clinical remission without surgery, 73.1% clinical response, 53.8% endoscopic improvement, and 44.2% endoscopic remission. The pediatric Week 52 remission rate (50%) closely matches the adult Week 12 responder rate in LUCENT-2 (50.7%). The lower bound of the 80% credible interval for pediatric remission (42.8%) exceeded the upper bound of the 90% credible interval for adult placebo (32.6%), supporting statistical robustness. Safety data show 6.3% experienced serious adverse events (none related to treatment), 3.2% discontinued due to UC flare, and no deaths, malignancies, opportunistic infections, or growth-related safety concerns occurred. The most common adverse events were mild or moderate. Over 26,000 children and adolescents in the U.S. are affected by UC, indicating significant market potential if approved. No financial or commercial impact data are disclosed.

Analysis

The announcement presents robust, realised clinical data from the SHINE-2 Phase 3 pediatric study, with clear primary and secondary endpoint results and safety outcomes. The positive tone is largely justified by these realised results, but the headline and narrative also emphasize future potential, such as regulatory submission for label expansion and Omvoh's possible first-in-class status for pediatric UC. About one-third of key claims are forward-looking, including regulatory plans and ongoing studies, but these are not exaggerated relative to the evidence. No financial or profitability metrics are disclosed, so the true_signal cannot exceed weak_positive. The execution distance for commercial benefit is long-term, as regulatory approval and market expansion are pending. There is no explicit large capital outlay tied to these results, and ongoing R&D is typical for the sector. The main gap is between the strong clinical narrative and the absence of any financial or commercial impact data.

Risk flags

• ●Regulatory approval is not guaranteed; while clinical data are strong, regulators may require additional evidence or raise concerns about pediatric safety or long-term outcomes.
• ●The SHINE-2 study is single-arm and open-label, which may introduce bias or limit direct comparability to placebo-controlled trials, potentially affecting regulatory or payer acceptance.
• ●Commercial impact is unquantified; the announcement provides no revenue, pricing, or market uptake projections, so the financial upside remains speculative until label expansion and reimbursement are secured.
• ●Long-term safety in pediatric populations is still being evaluated; while no new signals were observed at one year, ongoing monitoring is essential, and rare adverse events may emerge with broader use.
• ●Over half of enrolled patients had failed prior biologics, which may not reflect the broader pediatric UC population and could affect generalizability of results.

Bottom line

Lilly’s SHINE-2 Phase 3 data for Omvoh in pediatric ulcerative colitis show robust one-year efficacy and a safety profile consistent with adult use, positioning the drug for a potential first-in-class label expansion. The company is moving quickly to regulatory submission, but approval and commercial success are not assured. The absence of financial projections or commercial uptake data means investors cannot yet quantify the revenue impact. Key risks include regulatory uncertainty, the open-label study design, and the need for continued safety monitoring in children. If Omvoh secures approval, it could address a significant unmet need for over 26,000 pediatric UC patients in the U.S. alone, but investors should watch for regulatory feedback and future disclosures on market access and uptake.

Announcement summary

(NYSE:LLY) Eli Lilly and Company announced positive one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis (UC). In the single-arm, open-label study, 81% of patients achieved clinical response to Omvoh induction at Week 12. Among responders, 50% achieved clinical remission at Week 52, meeting the study's primary endpoint. In key secondary outcomes at Week 52, 71.2% of patients who responded to Omvoh induction achieved symptomatic remission, 50% achieved corticosteroid-free clinical remission without surgery, 73.1% achieved clinical response, 53.8% achieved endoscopic improvement, and 44.2% achieved endoscopic remission. The pediatric Week 52 clinical remission rate was similar to the adult Week 12 responder rate in LUCENT-2 (50.7%). The lower bound of the 80% credible interval for the Week 52 pediatric remission rate among Week 12 responders (42.8%) exceeded the upper bound of the 90% credible interval for the adult placebo remission rate in LUCENT-2 (32.6%). Through Week 52, four patients (6.3%) experienced a serious adverse event, none considered related to study treatment, and two patients (3.2%) discontinued treatment due to UC flare. No deaths, malignancies, opportunistic infections, or growth-related safety concerns were reported through Week 52. The most common treatment-emergent adverse events were upper respiratory tract infection, injection site reaction, UC, headache, nasopharyngitis, and anemia, with most being mild to moderate in severity. SHINE-2 enrolled 63 participants ages 4 to 17, with 54% having previously experienced biologic treatment failure and half entering the study with severe disease activity. UC affects more than 26,000 children and adolescents in the United States. Omvoh is currently approved for adults with moderately to severely active UC and Crohn's disease in 47 countries, including the U.S., EU, Canada, and Japan, and as a single-injection maintenance regimen in several countries. Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric UC. If approved, Omvoh would be the first IL-23p19 inhibitor indicated for pediatric UC. Lilly continues to study mirikizumab in pediatric inflammatory bowel disease, including a long-term extension study in UC and Crohn's disease (NCT04844606), an ongoing Phase 3 study in pediatric Crohn's disease (NCT05509777), and combination studies with eltrekibart (NCT06598943), zotemtegrast (NCT07186101), and an FXR agonist (NCT07483099). The COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials are investigating mirikizumab with an incretin-based therapy in adults with UC or Crohn's disease and obesity or overweight with at least one additional weight-related comorbid condition. Mark Genovese, M.D., is senior vice president of Lilly Immunology development. Marla C. Dubinsky, M.D., is Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai and Chief of Pediatric Gastroenterology and Nutrition at Mount Sinai Kravis Children's Hospital. Dr. Dubinsky is a paid consultant for Lilly but has not been compensated for media work. Omvoh is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any excipients. Omvoh may increase the risk of infection, and treatment should not be initiated in patients with clinically important active infection until resolved. Evaluate patients for tuberculosis prior to initiating Omvoh. Drug-induced liver injury has been reported; liver enzymes and bilirubin should be monitored. Avoid use of live vaccines in patients treated with Omvoh. Most common adverse reactions (≥2% and higher than placebo) in UC treatment include upper respiratory tract infections and arthralgia during induction, and upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection during maintenance.

Disagree with this article?